JP2017066161A5 - - Google Patents

Download PDF

Info

Publication number
JP2017066161A5
JP2017066161A5 JP2017000444A JP2017000444A JP2017066161A5 JP 2017066161 A5 JP2017066161 A5 JP 2017066161A5 JP 2017000444 A JP2017000444 A JP 2017000444A JP 2017000444 A JP2017000444 A JP 2017000444A JP 2017066161 A5 JP2017066161 A5 JP 2017066161A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
administration
subject
expression
increased
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017000444A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017066161A (ja
JP6385476B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017066161A publication Critical patent/JP2017066161A/ja
Publication of JP2017066161A5 publication Critical patent/JP2017066161A5/ja
Application granted granted Critical
Publication of JP6385476B2 publication Critical patent/JP6385476B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017000444A 2005-09-16 2017-01-05 Ｃｄ３６の発現を減少させる方法 Active JP6385476B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71817005P 2005-09-16 2005-09-16
US60/718,170 2005-09-16

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015156656A Division JP6175107B2 (ja) 2005-09-16 2015-08-07 Ｃｄ３６の発現を減少させる方法

Publications (3)

Publication Number Publication Date
JP2017066161A JP2017066161A (ja) 2017-04-06
JP2017066161A5 true JP2017066161A5 (enExample) 2017-06-29
JP6385476B2 JP6385476B2 (ja) 2018-09-05

Family

ID=37889419

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2008531412A Active JP5416971B2 (ja) 2005-09-16 2006-09-18 Ｃｄ３６の発現を減少させる方法
JP2012181082A Active JP5805596B2 (ja) 2005-09-16 2012-08-17 Ｃｄ３６の発現を減少させる方法
JP2013006199A Active JP5809649B2 (ja) 2005-09-16 2013-01-17 Ｃｄ３６の発現を減少させる方法
JP2015115856A Active JP6157539B2 (ja) 2005-09-16 2015-06-08 Ｃｄ３６の発現を減少させる方法
JP2015156656A Active JP6175107B2 (ja) 2005-09-16 2015-08-07 Ｃｄ３６の発現を減少させる方法
JP2017000444A Active JP6385476B2 (ja) 2005-09-16 2017-01-05 Ｃｄ３６の発現を減少させる方法

Family Applications Before (5)

Application Number Title Priority Date Filing Date
JP2008531412A Active JP5416971B2 (ja) 2005-09-16 2006-09-18 Ｃｄ３６の発現を減少させる方法
JP2012181082A Active JP5805596B2 (ja) 2005-09-16 2012-08-17 Ｃｄ３６の発現を減少させる方法
JP2013006199A Active JP5809649B2 (ja) 2005-09-16 2013-01-17 Ｃｄ３６の発現を減少させる方法
JP2015115856A Active JP6157539B2 (ja) 2005-09-16 2015-06-08 Ｃｄ３６の発現を減少させる方法
JP2015156656A Active JP6175107B2 (ja) 2005-09-16 2015-08-07 Ｃｄ３６の発現を減少させる方法

Country Status (10)

Country Link
US (10) US7541340B2 (enExample)
EP (5) EP3260127B1 (enExample)
JP (6) JP5416971B2 (enExample)
KR (9) KR20140106761A (enExample)
CN (6) CN101296704B (enExample)
AU (1) AU2006292352B2 (enExample)
CA (8) CA2622911C (enExample)
DK (1) DK1931369T3 (enExample)
HK (1) HK1206971A1 (enExample)
WO (1) WO2007035640A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2865385B1 (en) 2003-02-04 2016-11-16 Cornell Research Foundation, Inc. Uses of aromatic-cationic peptide
ZA200509229B (en) * 2003-05-01 2007-03-28 Cornell Res Foundation Inc Method and carrier complexes for delivering molecules to cells
CA2971928C (en) * 2004-01-23 2019-01-08 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US7687243B1 (en) * 2005-06-06 2010-03-30 Crook Tonia M Automated method for detecting apoptosis in cells
EP3260127B1 (en) * 2005-09-16 2019-05-01 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method of treating cerebral ischemia
PL2252312T3 (pl) * 2008-02-07 2014-10-31 Univ Cornell Sposoby zapobiegania lub leczenia insulinooporności
JP5677096B2 (ja) * 2008-02-26 2015-02-25 コーネル ユニヴァーシティー 急性腎障害を予防および治療するための方法
EP3563862B1 (en) * 2009-03-20 2021-05-05 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries
CN105031605A (zh) * 2009-08-12 2015-11-11 康奈尔大学 预防或治疗代谢综合症的方法
EP3150215A1 (en) * 2009-08-24 2017-04-05 Stealth Peptides International, Inc. Methods and compositions for preventing or treating opthalmic conditions
CN102711785A (zh) 2009-10-05 2012-10-03 康奈尔大学 预防或治疗心力衰竭的方法
CN103751763A (zh) * 2009-12-31 2014-04-30 康肽德生物医药技术有限公司 用于预防或治疗血管阻塞损伤的方法
EP3100739A1 (en) * 2009-12-31 2016-12-07 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
WO2011153209A2 (en) * 2010-06-01 2011-12-08 Cornell University Cd36 inhibition to control obesity and insulin sensitivity
CN105879008A (zh) * 2010-07-09 2016-08-24 康德生物医疗技术公司 预防或治疗缺血/再灌注损伤之后无复流的方法
EP3078384A1 (en) * 2012-02-22 2016-10-12 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
EP3170506B1 (en) * 2012-03-30 2018-05-16 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment neuropathy
CN104661670A (zh) * 2012-08-02 2015-05-27 康肽德生物医药技术有限公司 用于治疗动脉粥样硬化的方法
WO2014095875A1 (en) * 2012-12-18 2014-06-26 Per Olof Berggren Methods for treating and/or limiting development of diabetes
CN105579054A (zh) * 2013-05-14 2016-05-11 康德生物医疗技术公司 预防或治疗左心室重塑的方法
CA2916492A1 (en) * 2013-06-27 2014-12-31 Stealth Biotherapeutics Corp Peptide therapeutics and methods for using same
CN106163537A (zh) * 2013-09-30 2016-11-23 康奈尔大学 心磷脂靶向肽抑制β‑淀粉样蛋白寡聚物毒性
US9895410B2 (en) * 2013-12-12 2018-02-20 Cornell University Methods for preventing and treating oral cancers
EP3082838A4 (en) * 2013-12-16 2017-07-26 Cornell University Methods and compositions for treating and preventing cognitive dysfunction
CN107041946A (zh) * 2017-03-24 2017-08-15 南京大学 化合物ss‑31在制备治疗动脉粥样硬化及相关疾病药物或制剂上的应用
US11392555B2 (en) 2019-05-15 2022-07-19 Pure Storage, Inc. Cloud-based file services
US20220288013A1 (en) * 2019-07-26 2022-09-15 The Board Of Trustees Of The Leland Stanford Junior University 1,8-cineol coated implants
BR112022009804A2 (pt) 2019-11-20 2022-08-16 Univ Leland Stanford Junior Tratamento profilático da pele para radioterapia
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法
WO2025021993A1 (en) 2023-07-27 2025-01-30 Omnilinx Therapeutics Ag Endocytic and scavenger receptor-targeting chimeric proteins and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0350221B1 (en) 1988-06-30 1996-04-17 Astra Aktiebolag Dermorphin analogs, their methods of preparation, pharmaceutical compositions, and methods of therapeutic treatment using the same
US5602100A (en) 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
US5674980A (en) 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
EP0747092B1 (en) 1995-06-09 2003-12-03 Hisamitsu Pharmaceutical Co., Inc. Matrix for iontophoresis
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
FR2756284B1 (fr) * 1996-11-26 2000-04-28 Adir Nouveaux derives du benzopyrane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5885958A (en) 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
WO1999029721A1 (en) 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
CA2329709A1 (en) 1998-04-24 1999-11-04 Mitokor Compounds and methods for treating mitochondria-associated diseases
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
SE9900961D0 (sv) 1999-03-16 1999-03-16 Astra Ab Novel compounds
EP1218544B1 (en) 1999-10-04 2009-06-03 The University of Medicine and Dentistry of New Jersey TAR RNA binding peptides
US6759520B1 (en) 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) * 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
US7498297B2 (en) 2000-07-18 2009-03-03 Cornell Research Foundation Medicinal uses of mu-opioid receptor agonists
US6900178B2 (en) 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
DE10051983A1 (de) * 2000-10-20 2002-06-13 Beate Kehrel Inhibierung der pathogenen Wirkung oxidierter Proteine
ATE406908T1 (de) * 2000-10-20 2008-09-15 Hamburger Stiftung Zur Foerder Oxidierte proteine und deren biologische und therapeutische aktivität sowie diagnostische verwendung über die hemmung der interaktion zwischen oxidierten proteinen und cd36
AU2002256092C1 (en) 2001-04-05 2009-10-15 Collagenex Pharmaceuticals, Inc. Controlled delivery of tetracycline compounds and tetracycline derivatives
US20070015146A1 (en) 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
AU2002360460A1 (en) * 2001-12-03 2003-06-17 Nuvelo, Inc. Methods and materials relating to novel polypeptides and polynucleotides
JP4346870B2 (ja) * 2002-07-05 2009-10-21 キッコーマン株式会社 血糖値上昇抑制用組成物
WO2004017986A1 (en) * 2002-08-23 2004-03-04 Valorisation-Recherche, Societe En Commandite Growth hormone-releasing peptides in the treatment of prevention of atherosclerosis and hypercholesterolemia
EP2865385B1 (en) 2003-02-04 2016-11-16 Cornell Research Foundation, Inc. Uses of aromatic-cationic peptide
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
ZA200509229B (en) 2003-05-01 2007-03-28 Cornell Res Foundation Inc Method and carrier complexes for delivering molecules to cells
MXPA05011830A (es) 2003-05-09 2006-01-26 Novo Nordisk As Peptidos para uso en el tratamiento de la obesidad.
US20050012597A1 (en) 2003-07-02 2005-01-20 Anderson Peter Traneus Wireless electromagnetic tracking system using a nonlinear passive transponder
WO2005032481A2 (en) * 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
EP1529533A1 (en) * 2003-11-06 2005-05-11 Sahltech I Göteborg AB Use of GH secretagogues in hypoxic-ischemic brain injury
KR20060114713A (ko) 2003-12-12 2006-11-07 도꾸리쯔교세이호징 가가꾸 기쥬쯔 신꼬 기꼬 멕신/ＲＡＧＥ/ｉＮＯＳ 발현 질환 모델동물 및 상기 동물을 사용한 화합물의 평가방법
CA2971928C (en) * 2004-01-23 2019-01-08 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US20050272101A1 (en) 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
US8157123B2 (en) * 2005-02-23 2012-04-17 The Glad Products Company Container
EP3260127B1 (en) 2005-09-16 2019-05-01 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method of treating cerebral ischemia
US20070259377A1 (en) 2005-10-11 2007-11-08 Mickey Urdea Diabetes-associated markers and methods of use thereof
US20080027082A1 (en) 2006-06-19 2008-01-31 Berthold Hocher Use of adenosine a1 antagonists in radiocontrast media induced nephropathy
PL2252312T3 (pl) * 2008-02-07 2014-10-31 Univ Cornell Sposoby zapobiegania lub leczenia insulinooporności
JP5677096B2 (ja) 2008-02-26 2015-02-25 コーネル ユニヴァーシティー 急性腎障害を予防および治療するための方法
JP2012181082A (ja) * 2011-03-01 2012-09-20 Tokyo Electric Power Co Inc:The 仕切弁の分解点検補助装置およびその案内治具、並びに仕切弁の分解点検方法
CN202756379U (zh) 2012-07-13 2013-02-27 滨中元川金属制品（昆山）有限公司 一种自攻牙螺丝

Similar Documents

Publication Publication Date Title
JP2017066161A5 (enExample)
JP2015164953A5 (enExample)
JP2016053040A5 (enExample)
JP2010222367A5 (enExample)
CL2011000170A1 (es) Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
PH12015501623A1 (en) Glyco-modified atrial natriuretic peptide
CL2016000008A1 (es) Tratamiento de lesiones inflamatorias de rosacea con ivermectina.
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
MX2022008277A (es) Composiciones de gel para administracion transdermica para maximizar las concentraciones de farmaco en el estrato corneo y suero, y metodos de uso de las mismas.
PE20160012A1 (es) Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral
MX2011012143A (es) Composiciones adecuadas para el tratamiento topico o infecciones fungicas de la piel y uñas.
CO7151496A2 (es) Agentes terapeúticos para administración subcutánea optimizados
IL307992A (en) Parasitic formulations containing isoxazoline and methods for treating blepharitis
MX394496B (es) Administracion de metabolitos de berberina
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
PE20190210A1 (es) Aplicaciones de carrimicina en la infeccion por micobacterium tuberculosis resistente
CL2015000891A1 (es) Compuestos derivados de fenil-etinilo, moduladores de la actividad del receptor mglur5; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de la ansiedad, dolor, depresion,entre otras.
CL2013003700A1 (es) Composicion farmaceutica oftalmologica topica que comprende regorafenib, el cual se encuentra suspendido en un vehiculo farmaceuticamente aceptable; procedimiento de fabricacion y su uso para tratar o prevenir un trastorno oftalmologico.
WO2016030899A8 (en) Methods of treating amyotrophic lateral scleroses
MX2016007682A (es) Composicion farmaceutica que comprende ivabradina amorfa.
JP2007119497A5 (enExample)
EA201071138A1 (ru) Применение дронедарона для получения лекарственного средства для лечения пациентов с аритмией и с повышенным уровнем креатинина в результате введения дронедарона
PE20151300A1 (es) Composicion antifungica topica para el tratamiento de onicomicosis
MX2020003697A (es) Formulaciones farmaceuticas que comprenden un agonista del receptor opioide como ingredientes activos, metodos de fabricacion y usos terapeuticos de las mismas.
MX2015009681A (es) Un medicamento combinado que comprende finilefrina y paracetamol.